breast cancer Archives
Study to test combination therapy for breast cancer
Oct. 26, 2017—Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.
My Southern Health: How to assess your breast cancer risk
Oct. 20, 2017—Do you know what it means to be at “high” or “elevated” risk for developing breast cancer? Do you know if you are at high risk?
Breast Cancer Genomic Profiling Reveals Clues to Treatment Resistance
Aug. 9, 2017—Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers.
Stress may switch on bone “mets”
Aug. 9, 2017—New findings could explain the link between chronic stress and reduced survival in women diagnosed with breast cancer, and could lead to new strategies to improve treatment outcomes.
Investigators match novel cancer mutations with potential therapies
Aug. 3, 2017—Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.
Drivers of breast cancer metastasis
Jul. 20, 2017—Signaling through a complex of proteins called mTORC2 plays a role in breast cancer migration, invasion and metastasis, Vanderbilt researchers reported.
Arteaga to direct UT Southwestern cancer center
Jul. 13, 2017—Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center in Dallas.
STINGing combination for cancer
Jun. 19, 2017—A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.
VICC experts to discuss high risk breast cancer at free seminar June 6
May. 26, 2017—Vanderbilt-Ingram Cancer Center (VICC), in collaboration with the Hereditary Cancer Program and the Vanderbilt Breast Center, is hosting a free seminar, “Are You at High Risk for Breast Cancer?”
Study examines new breast cancer drug combination
Apr. 20, 2017—A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.
Horn to lead lung cancer combination therapy trial
Mar. 30, 2017—Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer.
Research support
Mar. 30, 2017—DS Services of America Inc. recently presented a $100,000 gift to Vanderbilt-Ingram Cancer Center (VICC) to support breast cancer research.
